Wall Street Healthcare Stock Coverage: 4 Stocks With New Price Targets

Here are the companies for which stock analysts initiated coverage in the Healthcare sector for the week ending December 23rd, 2011:

Zalicus (NASDAQ:ZLCS): MLV & Co initiated coverage of this company with a rating of Buy and a price target of $4 on Dec 21st. The shares recently traded at $1.33, up $0.04, or 3.1% since the analyst’s rating. About the company: Zalicus Inc is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. The Company’s drug pipeline includes an arthritis formula in phase 2 development. Get the most recent company news and stock data here >>

NewLink Genetics (NASDAQ:NLNK): Canaccord Genuity initiated coverage of this company with a rating of Buy and a price target of $11. Robert W. Baird initiated coverage of this company with a rating of Outperform and a price target of $10. Stifel Nicolaus initiated coverage of this company with a rating of Buy and a price target of $16 on Dec 21st. The shares recently traded at $7.17, up $0.17, or 2.43% since the analyst’s rating. About the company: NewLink Genetics Corporation is a biopharmaceutical company. The Company develops and commercializes biologic and small-molecule immunotherapy products intended to treat a wide range of cancers. NewLink’s products are designed to harness components of the patient’s immune system to fight cancer either alone or in combination with other treatment regimens. Get the most recent company news and stock data here >>

MEDNAX (NYSE:MD): BB&T Capital Mkts initiated coverage of this company with a rating of Buy and a price target of $80 on Dec 22nd. The shares recently traded at $70.52, up $0.23, or 0.33% since the analyst’s rating. About the company: MEDNAX, Inc., through a subsidiary, provides physician management services to hospital-based neonatal, maternal – fetal, pediatric cardiology, and pediatric intensive care specialties. The Company also manages anesthesia practices. Get the most recent company news and stock data here >>

ViroPharma (NASDAQ:VPHM): Brean Murray initiated coverage of this company with a rating of Buy and a price target of $37 on Dec 22nd. The shares recently traded at $27.77, down $0.06, or 0.22% since the analyst’s rating. About the company: ViroPharma Incorporated is a biopharmaceutical company committed to the commercialization, development, and discovery of new medicines. The Company’s products include a treatment for prophylaxis of hereditary angioedema as well a capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection and enterocolitis. Get the most recent company news and stock data here >>

(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>